Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-01-10
2006-01-10
Aulakh, Charanjit S. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S099000, C544S184000, C544S343000, C546S070000, C514S243000, C514S250000, C514S285000
Reexamination Certificate
active
06984641
ABSTRACT:
Selective inhibitors of cGMP-specific PDE, and use of the compounds and salts and solvates thereof as therapeutic agents, are disclosed.
REFERENCES:
patent: 5218119 (1993-06-01), Kreidl et al.
patent: 5747520 (1998-05-01), Pommier et al.
patent: 6143746 (2000-11-01), Daugan et al.
patent: WO 95/19978 (1995-07-01), None
patent: WO 97/03985 (1997-02-01), None
patent: WO 97/43287 (1997-11-01), None
patent: WO 00/15639 (2000-03-01), None
patent: WO 01/87038 (2001-11-01), None
patent: WO 01/94347 (2001-12-01), None
patent: WO 02/28859 (2002-04-01), None
Edmund Sybetz et al., “Inhibitors of PDE1 and PDE5 cGMP Phosphodiesterases: patents and therapeutic potential”,Expert Opinion on Therapeutic Patents, 7(6):631-639 (1997).
Bombrun Agnes
Brown Raymond F.
Daugan Alain C.
Gellibert Françoise
Gosmini Romain L.
Aulakh Charanjit S.
Lilly Icos LLC.
Marshall & Gerstein & Borun LLP
LandOfFree
Carboline derivatives as PDE5 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carboline derivatives as PDE5 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carboline derivatives as PDE5 inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3556161